Table 1.

Baseline demographics and clinical characteristics

	Placebo (n = 503)	Adalimumab (n = 966)
Age, mean ± SD, years	45 ± 13	44 ± 13
Male, %	65	67
White, %	91	92
Body weight, mean ± SD, kg	93 ± 23	92 ± 23
Psoriasis duration, mean ± SD, years	19 ± 11	18 ± 12
BSA affected, mean ± SD, %	26 ± 15	27 ± 16
PASI score, mean ± SD	19 ± 7	19 ± 7
Psoriatic arthritis, %	28	27

BSA body surface area, PASI Psoriasis Area and Severity Index, SD standard deviation